Surgical Neurology
Volume 65, Issue 1 , Pages 11-17 , January 2006

Intracranial hemangiopericytomas: correlation of topoisomerase IIα expression with biologic behavior

  • Geeta Chacko, MD

      Affiliations

    • Division of Neuropathology, Department of Neurological Sciences, Christian Medical College and Hospital, Vellore 632004, India
    • Corresponding Author InformationCorresponding author. Tel.: +91 416 2282185, 2282018; fax: +91 416 2232035, 2232103.
    • ,
  • Ari G. Chacko, MCh

      Affiliations

    • Division of Neurosurgery, Department of Neurological Sciences, Christian Medical College and Hospital, Vellore 632004, India
    • ,
  • Vedantam Rajshekhar, MCh

      Affiliations

    • Division of Neurosurgery, Department of Neurological Sciences, Christian Medical College and Hospital, Vellore 632004, India
    • ,
  • Jayaprakash P. Muliyil, MD

      Affiliations

    • Department of Community Health, Christian Medical College and Hospital, Vellore 632004, India

Received 25 January 2005 ,Accepted 3 August 2005.

References 

  1. Alen JF, Lobato RD, Gomez PA, et al. Intracranial hemangiopericytoma: study of 12 cases. Acta Neurochir (Wien). 2001;143:575–586
  2. Bildrici K, Tel N, Ozalp SS, et al. Prognostic significance of DNA topoisomerase II-alpha (Ki-S1) immunoexpression in endometrial carcinoma. Eur J Gynaecol Oncol. 2002;23:540–544
  3. Brustmann H, Naude S. Expression of topoisomerase IIalpha, Ki-67, proliferating cell nuclear antigen, p53, and argyrophilic nucleolar organizer regions in vulvar squamous lesions. Gynecol Oncol. 2002;86:192–199
  4. Coffey RJ, Cascino TL, Shaw EG. Radiosurgical treatment of recurrent hemangiopericytomas of the meninges: preliminary results. J Neurosurg. 1993;78:903–908
  5. Ecker RD, Marsh WR, Pollock BE, et al. Hemangiopericytoma in the central nervous system: treatment, pathological features, and long-term follow-up in 38 patients. J Neurosurg. 2003;98:1182–1187
  6. Galanis E, Buckner JC, Scheithauer BW, et al. Management of recurrent meningeal hemangiopericytoma. Cancer. 1998;82:1915–1920
  7. Guthrie BL, Ebersold MJ, Scheithauer BW, et al. Meningeal hemangiopericytoma: histopathological features, treatment, and long-term follow-up of 44 cases. Neurosurgery. 1989;25:514–522
  8. Hafian H, Venteo L, Sukhanova A, et al. Immunohistochemical study of DNA topoisomerase I, DNA topoisomerase IIalpha, p53, and Ki-67 in oral preneoplastic lesions and oral squamous cell carcinomas. Hum Pathol. 2004;35:745–751
  9. Hendricks JBWE. Quality control considerations for Ki-67 detection and quantitation in paraffin-embedded tissue. J Cell Biochem Suppl. 1994;19:105–110
  10. Holden JA, Townsend JJ. DNA topoisomerase II-alpha as a proliferation marker in astrocytic neoplasms of the central nervous system: correlation with MIB1 expression and patient survival. Mod Pathol. 1999;12:1094–1100
  11. Jaaskelainen J, Servo A, Haltia M, et al. Intracranial hemangiopericytoma: radiology, surgery, radiotherapy, and outcome in 21 patients. Surg Neurol. 1985;23:227–236
  12. Konstantinidou AE, Patsouris E, Korkolopoulou P, et al. DNA topoisomerase IIalpha expression correlates with cell proliferation but not with recurrence in intracranial meningiomas. Histopathology. 2001;39:402–408
  13. Koren R, Kugel V, Dekel Y, et al. Human DNA topoisomerase-IIalpha expression as a prognostic factor for transitional cell carcinoma of the urinary bladder. BJU Int. 2003;91:489–492
  14. Korkolopoulou P, Angelopoulou M, Siakantari M, et al. Evaluation of DNA topoisomerase IIalpha expression provides independent prognostic information in non-Hodgkin's lymphomas. Histopathology. 2001;38:45–53
  15. Korkolopoulou P, Patsouris E, Konstantinidou AE, et al. Mitosin and DNA topoisomerase IIalpha: two novel proliferation markers in the prognostication of diffuse astrocytoma patient survival. Appl Immunohistochem Mol Morphol. 2001;9:207–214
  16. Koshiyama M, Fujii H, Kinezaki M, et al. Correlation between topo II alpha expression and chemosensitivity testing for topo II–targeting drugs in gynaecological carcinomas. Anticancer Res. 2001;21:905–910
  17. Kunishio K, Morisaki K, Matsumoto Y, et al. DNA topoisomerase IIalpha protein and mRNA expression in intracranial meningiomas. Brain Tumor Pathol. 2000;17:105–110
  18. MacGrogan G, Rudolph P, Mascarel Id I, et al. DNA topoisomerase IIalpha expression and the response to primary chemotherapy in breast cancer. Br J Cancer. 2003;89:666–671
  19. Mena H, Ribas JL, Pezeshkpour GH, et al. Hemangiopericytoma of the central nervous system: a review of 94 cases. Hum Pathol. 1991;22:84–91
  20. Miettinen HE, Jarvinen TA, Kellner U, et al. High topoisomerase IIalpha expression associates with high proliferation rate and poor prognosis in oligodendrogliomas. Neuropathol Appl Neurobiol. 2000;26:504–512
  21. Mira JGCF, Fortner JG. The role of radiotherapy in the management of malignant hemangiopericytoma: report of eleven new cases and review of the literature. Cancer. 1977;39:1254–1259
  22. Nunnery EWKL, Reddick RL, Lipper S. Hemangiopericytoma: a light microscopic and ultrastructural study. Cancer. 1981;47(5):906–914
  23. Park K, Kim J, Lim S, et al. Topoisomerase II-alpha (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy. Eur J Cancer. 2003;39:631–634
  24. Probst-Cousin SBM, Schroder R, Kuchelmeister K, et al. Ki-67 and biological behaviour in meningeal haemangiopericytomas. Histopathology. 1996;29:57–61
  25. Provencio M, Corbacho C, Salas C, et al. The topoisomerase IIalpha expression correlates with survival in patients with advanced Hodgkin's lymphoma. Clin Cancer Res. 2003;9:1406–1411
  26. Rees M, Stahl M, Klump B, et al. The prognostic significance of proliferative activity, apoptosis and expression of DNA topoisomerase II alpha in multimodally-treated oesophageal squamous cell carcinoma. Anticancer Res. 2001;21:3637–3642
  27. Roessler K, Gatterbauer B, Kitz K. Topoisomerase II alpha as a reliable proliferation marker in meningiomas. Neurol Res. 2002;24:241–243
  28. Servo A, Jaaskelainen J, Wahlstrom T, et al. Diagnosis of intracranial haemangiopericytomas with angiography and CT scanning. Neuroradiology. 1985;27:38–43
  29. Sheehan J, Kondziolka D, Flickinger J, et al. Radiosurgery for treatment of recurrent intracranial hemangiopericytomas. Neurosurgery. 2002;51:905–910[discussion 901-910]
  30. Taniguchi KWT, Yoshida T, Mizuno M, et al. Immunohistochemical staining of DNA topoisomerase IIalpha in human gliomas. J Neurosurg. 1999;91:477–482
  31. Vuorinen V, Sallinen P, Haapasalo H, et al. Outcome of 31 intracranial haemangiopericytomas: poor predictive value of cell proliferation indices. Acta Neurochir (Wien). 1996;138:1399–1408
  32. Yabuki NSH, Kato K, Ohara S, et al. Immunohistochemical study of DNA topoisomerase II in human gastric disorders. Am J Pathol. 1996;149:997–1007

PII: S0090-3019(05)00611-7

doi: 10.1016/j.surneu.2005.08.013

Surgical Neurology
Volume 65, Issue 1 , Pages 11-17 , January 2006

Article Tools

* Image Usage & Resolution